Abstract:Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Clinical presentation and disease course are highly heterogeneous. Typically, disease progression occurs over time and is characterized by the gradual accumulation of disability. The risk of developing MS is driven by complex interactions between genetic and environmental factors, including the gut microbiome. How the commensal gut microbiota impacts disease severity and progression over time remains unknown. In a longitudinal study, disability status and associated clinical features in 58 MS patients were tracked over 4.2 ± 0.98 years, and the baseline fecal gut microbiome was characterized via 16S amplicon sequencing. Progressor status, defined as patients with an increase in Expanded Disability Status Scale (EDSS), were correlated with features of the gut microbiome to determine candidate microbiota associated with risk of MS disease progression. We found no overt differences in microbial community diversity and overall structure between MS patients exhibiting disease progression and non-progressors. However, a total of 41 bacterial species were associated with worsening disease, including a marked depletion in Akkermansia, Lachnospiraceae, and Oscillospiraceae, with an expansion of Alloprevotella, Prevotella-9, and Rhodospirillales. Analysis of the metabolic potential of the inferred metagenome from taxa associated with progression revealed enrichment in oxidative stress-inducing aerobic respiration at the expense of microbial vitamin K2 production (linked to Akkermansia), and a depletion in SCFA metabolism (linked to Oscillospiraceae). Further, as a proof of principle, statistical modeling demonstrated that microbiota composition and clinical features were sufficient to predict disease progression. Additionally, we found that constipation, a frequent gastrointestinal comorbidity among MS patients, exhibited a divergent microbial signature compared with progressor status. These results demonstrate a proof of principle for the utility of the gut microbiome for predicting disease progression in MS in a small well-defined cohort. Further, analysis of the inferred metagenome suggested that oxidative stress, vitamin K2, and SCFAs are associated with progression, warranting future functional validation and mechanistic study.

Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review

The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study

The Multiple Sclerosis Gut Microbiota: A Systematic Review

Modulating the Gut Microbiome in Multiple Sclerosis Management: A Systematic Review of Current Interventions

Changes in Gut Microbiota in Patients with Multiple Sclerosis Based on 16s rRNA Gene Sequencing Technology: A Review and Meta-Analysis

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes

Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet

Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy

Feeding the gut microbiome: impact on multiple sclerosis

Meta-analysis identifies common gut microbiota associated with multiple sclerosis

The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis

The Gut Microbiota and Associated Metabolites in Multiple Sclerosis

The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis

Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis

Gut-Microbiota, and Multiple Sclerosis: Background, Evidence, and Perspectives

Mycobacterium avium subspecies paratuberculosis (MAP) infection, and its impact on gut microbiome of individuals with multiple sclerosis

Involvement of gut microbiota in multiple sclerosis—review of a new pathophysiological hypothesis and potential treatment target

Bacteria–Fungi Interactions in Multiple Sclerosis

Targeting the gut to treat multiple sclerosis

Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis

Causal effects of gut microbiota on multiple sclerosis: A two‐sample Mendelian randomization study